RecruitingNot ApplicableNCT06389149

Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease


Sponsor

University of Nebraska

Enrollment

24 participants

Start Date

Aug 16, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to test the effects of leg exercise assistive paddling (LEAP) therapy during prolonged sitting (PS) on vascular and functional performance in those with peripheral artery disease (PAD) and age-matched controls. LEAP therapy is a novel application of passive limb movement to enhance blood flow through the legs without muscular contractions. Specifically, LEAP therapy is the rotational passive movement of the lower leg about the knee from 90 to 180 degrees of rotation at a cadence of 1Hz. Previous literature has indicated that this movement pattern can produce robust increases in blood flow in the passively moved limb in healthy individuals, and passive limb movement may protect vascular function during PS. However, the impact of LEAP therapy to improve blood flow in the legs of those with PAD during PS is unknown. Participants will participate in a randomized cross-over design study with 2 visits (LEAP therapy and no LEAP therapy). For the first visit, participants will be randomly allocated to receive LEAP therapy during 2.5 hours of PS or not. For the second visit, participants will sit for 2.5 hours and will receive the condition that they did not previously receive. Before and after PS, the following measurements will be made: flow-mediated dilation of the popliteal and brachial arteries, arterial stiffness with tonometry techniques, microvascular vasodilatory capacity and skeletal muscle metabolic rate with near-infrared spectroscopy, autonomic nervous system function, and there will be blood drawn from the antecubital vein. After PS, participants will participate in a graded exercise test to assess functional walking capacity. Finally, during PS, near-infrared spectroscopy on the calf muscles and electrocardiogram will be collected continuously to monitor muscle oxygen availability and autonomic activity, respectively.


Eligibility

Min Age: 55 YearsMax Age: 85 Years

Inclusion Criteria12

  • PAD subjects:
  • Able to provide written informed consent
  • years of age
  • Diagnosed with Peripheral Arterial Disease (PAD) Fontaine stage II-III
  • Women must be postmenopausal (cessation of menses for \> 24 months)
  • History of exercise-induced claudication
  • Free of ulcers, gangrene, or necrosis of the foot, Fontaine stage IV PAD
  • Age-matched control subjects:
  • Able to provide written informed consent
  • years of age
  • No evidence of peripheral occlusive disease, ankle-brachial index \> 0.90
  • Women must be postmenopausal (cessation of menses for \> 24 months)

Exclusion Criteria14

  • PAD subjects:
  • Pain at rest and/or tissue loss from Peripheral Arterial Disease (PAD), Fontaine stage IV PAD
  • Acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma
  • Limited walking capacity from conditions other than PAD
  • Have not had a physical exam to assess exercise limitations in the past year
  • Pregnant or nursing
  • Kidney disease or type II diabetes mellitus
  • Age-matched control subjects:
  • Positive diagnosis of Peripheral Arterial Disease (PAD)
  • Any exercise limitations as determined at last physical exam, at least 1 year prior to study
  • Have not had a physical exam to assess exercise limitations in the past year
  • Limited walking capacity from musculoskeletal injury
  • Pregnant or nursing
  • Kidney disease or type II diabetes mellitus

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERLEAP therapy

Knee bending from 90°-180° at 1Hz for 1 minute every 10 minutes during 2.5 hours of prolonged sitting

OTHERno LEAP therapy

2.5 hours of uninterrupted prolonged sitting (no movement)


Locations(1)

University of Nebraska - Omaha

Omaha, Nebraska, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06389149


Related Trials